A carbonated, oral rehydration beverage that includes about 25-75 mEq/L of sodium, about 15-40 mEq/L of potassium, about 20-55 mEq/L of chloride, dextrose, and at least about 2.0 volumes of CO.sub.2. A method of treating or preventing dehydration is also provided.

A carbonated, oral rehydration beverage that includes about 25-75 mEq/L of sodium, about 15-40 mEq/L of potassium, about 20-55 mEq/L of chloride, dextrose, and at least about 2.0 volumes of CO.sub.2. A method of treating or preventing dehydration is also provided.

The invention provides formulations for use in food products. The formulations provided herein are comprised of stabilizers, including modified food starches, sweeteners, dairy or non-dairy products, and optionally flavorings, and colorings. The formulations can be used in dessert food products, especially in tres leches cakes.

The invention provides formulations for use in food products. The formulations provided herein are comprised of stabilizers, including modified food starches, sweeteners, dairy or non-dairy products, and optionally flavorings, and colorings. The formulations can be used in dessert food products, especially in tres leches cakes.

A frozen confection comprising sugars in a total amount S of less than 21 wt % and amino acids in a total amount A of at least 0.75 wt %, wherein the frozen confection comprises at least one amino acid selected from: alanine, arginine, glycine, lysine, proline, serine, and dipeptides thereof.

A frozen confection comprising sugars in a total amount S of less than 21 wt % and amino acids in a total amount A of at least 0.75 wt %, wherein the frozen confection comprises at least one amino acid selected from: alanine, arginine, glycine, lysine, proline, serine, and dipeptides thereof.

The present disclosure provides pharmaceutical compositions including a cannabinoid acid ester compound alone or in combination with one or more additional cannabinoid compounds. In some embodiments, the cannabinoid acid ester compound is a tetrahydrocannabinolic acid (THCA) ester. In some embodiments, the cannabinoid acid ester compound is a cannabigerolic (CBGA) acid ester. In some embodiments, the cannabinoid acid ester compound is a cannabinolic (CBNA) acid ester. A variety of therapeutic applications in which the cannabinoid acid ester compounds and pharmaceutical compositions find use are also provided, including combination therapies using cannabinoid acid ester compounds and one or more additional therapeutic agents.

The present disclosure provides pharmaceutical compositions including a cannabinoid acid ester compound alone or in combination with one or more additional cannabinoid compounds. In some embodiments, the cannabinoid acid ester compound is a tetrahydrocannabinolic acid (THCA) ester. In some embodiments, the cannabinoid acid ester compound is a cannabigerolic (CBGA) acid ester. In some embodiments, the cannabinoid acid ester compound is a cannabinolic (CBNA) acid ester. A variety of therapeutic applications in which the cannabinoid acid ester compounds and pharmaceutical compositions find use are also provided, including combination therapies using cannabinoid acid ester compounds and one or more additional therapeutic agents.

The present application discloses a composition of a butyrate or a derivative thereof and benzoic acid, preparation method and use as a feedstuff additive thereof, wherein the composition comprises 5 wt % to 50 wt % of the butyrate or the derivative of butyric acid, and 50 wt % to 95 wt % of the benzoic acid or benzoate. The benzoate and butyrate dissociate into acidic molecules when they enter into animals' bodies. The butyric acid stimulates parietal cells to grown and the parietal cells produce hydrochloric acid, which thereby reduces the pH value in the stomach. Benzoic acid can inhibit facultative anaerobes such as Lactobacillus and butyric acid-producing anaerobic bacteria in the stomach, rendering the two floras become predominant microflora, and therefore produce more endogenous organic acids such as lactic acid and butyric acid. These acids are beneficial to gastrointestinal health and animal growth. As a result, a synergy effect of the two components in the composition is achieved.

The present invention relates to novel nutritional compositions useful in the treatment of neoplastic diseases. More specifically, the present invention provides for nutritional composition comprising at least resistant starch, proteins and fats, that is able to retard the cancer growth reducing the inflammatory state of the patient and avoiding chronic weight loss.